Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
The Clinical Picture

Minocycline-induced hyperpigmentation

Mahmoud Abdelghany, MD and Alan J. Kivitz, MD
Cleveland Clinic Journal of Medicine December 2016, 83 (12) 876-877; DOI: https://doi.org/10.3949/ccjm.83a.16058
Mahmoud Abdelghany
Department of Medicine, The State University of New York, Upstate Medical University, Syracuse, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: [email protected]
Alan J. Kivitz
President, Altoona Center for Clinical Research, Duncansville, PA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

A 64-year-old woman had a remote history of generalized fatigue, tightness of the hands, tingling and numbness of the face, joint stiffness, and bluish discoloration of the fingers that worsened with cold weather. Laboratory testing at that time had revealed an antinuclear antibody titer over 1:320 (reference range < 1:10), anti-Scl-70 antibody 100 U/mL (< 32 U/mL), and thyroid-stimulating hormone 10.78 mIU/L (0.4-5.5). Pulmonary function testing showed a pattern of restrictive lung disease. She was diagnosed with hypothyroidism, Raynaud phenomenon, and scleroderma. She was referred to a rheumatologist, who prescribed levothyroxine and penicillamine.

Despite treatment, she continued to feel fatigued, and she requested the addition of minocycline to the scleroderma treatment after seeing a report on television. Minocycline 100 mg twice daily was prescribed. She reported improvement of her symptoms for the next 2 years but was then lost to follow-up with the rheumatologist. She continued to take penicillamine and minocycline as prescribed by her primary care physician.

She presented to our clinic with bluish discoloration (Figure 1) that had started 1 year before as a small area but had spread to involve the entire face, fingers, gums, teeth, and sclera, and included a dark discoloration of the neck and upper chest. She had been taking minocycline for nearly 9 years. We referred her to a dermatologist, who diagnosed minocycline- induced hyperpigmentation. Her minocycline was stopped. Skin biopsy was not done, as the dermatologist was confident making the diagnosis without biopsy. At 1 year later, she continued to have the widespread skin pigmentation with no improvement at all.

FIGURE 1
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1

DIFFERENTIAL DIAGNOSIS

Hyperpigmentation is the darkening in the natural color of the skin, usually from increased deposition of melanin in the epidermis or dermis, or both. It can occur in different degrees of blue, brown, and black (from lightest to darkest). Less frequently, it may be caused by the deposition in the dermis of an endogenous or exogenous pigment, such as hemosiderin, iron, or heavy metal.1 The hyperpigmentation can be circumscribed or more diffuse.

The differential diagnosis of diffuse skin pigmentation includes Addison disease, hyperthyroidism, hemochromatosis, erythema dyschromicum perstans, cutaneous malignancies, sunburn, and drug-induced hyperpigmentation.1,2 Medications commonly cited as causing hyperpigmentation include minocycline, amiodarone, bleomycin, prostaglandins, oral contraceptives, phenothiazine, and antimalarial drugs.1,3 In Addison disease, the pigmentation is typically diffuse, with accentuation in sun-exposed areas, flexures, palmar and plantar creases, and areas of pressure or friction.2 The bronze discoloration of hemochromatosis is from a combination of hemosiderin deposition and increased melanin production.1 Erythema dyschromicum perstans presents with brownish oval-shaped macules and patches. Early lesions may have thin, raised, erythematous borders that typically involve the trunk, but they may spread to the neck, upper extremities, and face.4

The role of minocycline in the treatment of scleroderma is controversial. Early reports involving a small number of patients showed a benefit of minocycline in decreasing symptoms,5,6 but these findings were not achieved in a larger multicenter trial.7

Types of minocycline-induced hyperpigmentation

Three types of minocycline-induced hyperpigmentation occur3,8:

  • Type 1—blue-grey coloration on the face in areas of inflammation

  • Type 2—blue-grey coloration on normal skin on the skin of the shins and forearms

  • Type 3—the least common, characterized by diffuse muddy brown or blue-grey discoloration in sun-exposed areas, as in our patient.

The prevalence of minocycline-induced hyperpigmentation varies between 2.4% and 41% and is highest in patients with rheumatoid arthritis.3,9 Type 1 pigmentation is not correlated with treatment duration or cumulative dose, while type 2 and 3 are associated with long-term therapy.8 In type 3, changes are nonspecific, consisting of increased melanin in basal keratinocytes and melanin-only staining dermal melanophages. Types 1 and 2 may resolve slowly, whereas type 3 can persist indefinitely.3,8,10

TREATMENT

Treatment involves early recognition, discontinuation of the drug, and avoidance of sun exposure. Treatment with pigment-specific lasers has shown promise.8,10

  • Copyright © 2016 The Cleveland Clinic Foundation. All Rights Reserved.

REFERENCES

  1. ↵
    1. Stulberg DL,
    2. Clark N,
    3. Tovey D
    . Common hyperpigmentation disorders in adults: Part I. Diagnostic approach, café au lait macules, diffuse hyperpigmentation, sun exposure, and phototoxic reactions. Am Fam Physician 2003; 68:1955–1960.
    OpenUrlPubMed
  2. ↵
    1. Thiboutot DM
    . Clinical review 74: dermatological manifestations of endocrine disorders. J Clin Endocrinol Metab 1995; 80:3082–3087.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Geria AN,
    2. Tajirian AL,
    3. Kihiczak G,
    4. Schwartz RA
    . Minocycline-induced skin pigmentation: an update. Acta Dermatovenerol Croat 2009; 17:123–126.
    OpenUrlPubMed
  4. ↵
    1. Schwartz RA
    . Erythema dyschromicum perstans: the continuing enigma of Cinderella or ashy dermatosis. Int J Dermatol 2004; 43:230–232.
    OpenUrlPubMed
  5. ↵
    1. Le CH,
    2. Morales A,
    3. Trentham DE
    . Minocycline in early diffuse scleroderma. Lancet 1998; 352:1755–1756.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Robertson LP,
    2. Marshall RW,
    3. Hickling P
    . Treatment of cutaneous calcinosis in limited systemic sclerosis with minocycline. Ann Rheum Dis 2003; 62:267–269.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Mayes MD,
    2. O’Donnell D,
    3. Rothfield NF,
    4. Csuka ME
    . Minocycline is not effective in systemic sclerosis: results of an open-label multicenter trial. Arthritis Rheum 2004; 50:553–557.
    OpenUrlCrossRefPubMed
  8. ↵
    1. James WD,
    2. Berger TG,
    3. Elston DM
    . Andrews’ Diseases of the Skin: Clinical Dermatology. 11th ed. London, UK: Saunders/Elsevier; 2011:125–126.
  9. ↵
    1. Roberts G,
    2. Capell HA
    . The frequency and distribution of minocycline induced hyperpigmentation in a rheumatoid arthritis population. J Rheumatol 2006; 33:1254–1257.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Vangipuram RK,
    2. DeLozier WL,
    3. Geddes E,
    4. Friedman PM
    . Complete resolution of minocycline pigmentation following a single treatment with non-ablative 1550-nm fractional resurfacing in combination with the 755-nm Q-switched alexandrite laser. Lasers Surg Med 2016; 48:234–237.
    OpenUrl
PreviousNext
Back to top

In this issue

Cleveland Clinic Journal of Medicine: 83 (12)
Cleveland Clinic Journal of Medicine
Vol. 83, Issue 12
1 Dec 2016
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Minocycline-induced hyperpigmentation
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Minocycline-induced hyperpigmentation
Mahmoud Abdelghany, Alan J. Kivitz
Cleveland Clinic Journal of Medicine Dec 2016, 83 (12) 876-877; DOI: 10.3949/ccjm.83a.16058

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Minocycline-induced hyperpigmentation
Mahmoud Abdelghany, Alan J. Kivitz
Cleveland Clinic Journal of Medicine Dec 2016, 83 (12) 876-877; DOI: 10.3949/ccjm.83a.16058
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Linkedin Share Button

Jump to section

  • Article
    • DIFFERENTIAL DIAGNOSIS
    • TREATMENT
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Tinea incognito
  • Prolonged venous filling time and dependent rubor in a patient with peripheral artery disease
  • Sarcoidosis with diffuse purplish erythematous plaques on the hands
Show more The Clinical Picture

Similar Articles

Subjects

  • Dermatology
  • Diabetes
  • Rheumatology
  • Women's Health

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2025 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire